Merck & Co., Inc. (NYSE:MRK) reaffirmed its deep commitment to discovering and formulating novel medications in the global fight against severe infectious diseases. The company also known as MSD outside Canada and the U.S., will present over 30 scientific data presentations on the marketed and investigational anti-infective medicines. The presentations will be done at the 25th ECCMID, from April 25 to April 28, 2015 in Copenhagen, Denmark.
The expert speaks
Dr. Julie Gerberding of Merck said that the rise in infections resistant to existing antibiotics has translated into one of the most severe public health problems. The expert team is proud to reaffirm the company’s long-standing commitment to formulate new therapeutics to control infectious diseases, and to keep on collaborating with other groups to support antimicrobial stewardship in order to slow the rate of growing resistance.
Merck concluded its purchase of Cubist Pharmaceuticals, Inc. on January 21, 2015, and persists to build on both companies’ activities in infectious disease. The main focus is on antimicrobial research and portfolio of antifungal and antibiotic medicines, medicines for HCV and HIV and vaccines. There are multiple programs that extend discovery via late-stage development. As of now, Merck has over 15 ongoing clinical studies assessing antibiotic, antiviral and antifungal agents for the treatment and prevention of infectious disease. These studies are estimated to enroll almost 8,000 patients.
The innovation in formulating new anti-infective medications is crucial to resolve growing unmet medical needs and reduce the increasing problem of antifungal and antibiotic resistance. Apart from in-house anti-infective research measures, Merck extends its resources and expertise by collaborating with leading scientists around the world. It is committed to work with associates to help address unmet need. It understands that new measures and a broader scope of association with both private and public entities are essential to support innovation.